Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors Abstract #452

Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Aim(s): We describe an international validation study designed to assess the clinical and psychometric reliability, validity and responsiveness-to-change of the QLQ-GINET21 in patients with NETs.
Materials and methods: Two-hundred and fifty patients were recruited into this international multicenter study. The sites of NET included any gut or lung primary with metastases, or a pancreatic primary. The study required that all patients complete two HRQoL questionnaires – the EORTC QLQ-C30 (version 3.0) and the QLQ-GINET21 – at all assessment time points. Each was studied in two groups: Group 1 (somatostatin [SMS] analogues and Interferon) and Group 2 (all other treatments).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage

To read results and conclusion, please login ...

Further abstracts you may be interested in

#327 Long-term Results and Life Quality in Patients with Pancreatic Neuroendocrine Tumors at Munich University-Großhadern
Introduction: PNETs substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized centers, a broad interdiscipilary armentarium can be used to achieve optimal treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sabine Zahn
Authors: Zahn S, Reincke A, Hornung H, Jauch K W, ...
#1835 A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales
Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors
Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2130 Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service
Introduction: Patients with NETs have worse health-related quality of life (HRQoL) than the general population.
Technological advances have significantly increased electronic patient-reported outcome (ePRO) data collection capabilities.
There is little longitudinal PRO/ePRO data and limited data on gastrointestinal symptoms, particularly ‘diarrhoea’, in NET patients.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...